S&P 500   4,291.58 (-0.13%)
DOW   33,961.07 (+0.14%)
QQQ   331.49 (-0.47%)
AAPL   172.61 (-0.33%)
MSFT   292.63 (-0.29%)
META   178.63 (-1.25%)
GOOGL   121.82 (-0.21%)
AMZN   143.41 (+0.16%)
TSLA   939.16 (+1.21%)
NVDA   188.12 (-1.16%)
NIO   20.96 (-1.60%)
BABA   91.98 (-2.36%)
AMD   100.25 (-0.75%)
MU   63.67 (-1.59%)
T   18.40 (+0.05%)
CGC   3.67 (-3.93%)
F   16.35 (+0.18%)
GE   79.20 (-0.76%)
DIS   124.05 (-0.17%)
AMC   24.34 (+0.54%)
PYPL   100.94 (-0.56%)
PFE   49.68 (-0.14%)
NFLX   247.12 (-0.80%)
S&P 500   4,291.58 (-0.13%)
DOW   33,961.07 (+0.14%)
QQQ   331.49 (-0.47%)
AAPL   172.61 (-0.33%)
MSFT   292.63 (-0.29%)
META   178.63 (-1.25%)
GOOGL   121.82 (-0.21%)
AMZN   143.41 (+0.16%)
TSLA   939.16 (+1.21%)
NVDA   188.12 (-1.16%)
NIO   20.96 (-1.60%)
BABA   91.98 (-2.36%)
AMD   100.25 (-0.75%)
MU   63.67 (-1.59%)
T   18.40 (+0.05%)
CGC   3.67 (-3.93%)
F   16.35 (+0.18%)
GE   79.20 (-0.76%)
DIS   124.05 (-0.17%)
AMC   24.34 (+0.54%)
PYPL   100.94 (-0.56%)
PFE   49.68 (-0.14%)
NFLX   247.12 (-0.80%)
S&P 500   4,291.58 (-0.13%)
DOW   33,961.07 (+0.14%)
QQQ   331.49 (-0.47%)
AAPL   172.61 (-0.33%)
MSFT   292.63 (-0.29%)
META   178.63 (-1.25%)
GOOGL   121.82 (-0.21%)
AMZN   143.41 (+0.16%)
TSLA   939.16 (+1.21%)
NVDA   188.12 (-1.16%)
NIO   20.96 (-1.60%)
BABA   91.98 (-2.36%)
AMD   100.25 (-0.75%)
MU   63.67 (-1.59%)
T   18.40 (+0.05%)
CGC   3.67 (-3.93%)
F   16.35 (+0.18%)
GE   79.20 (-0.76%)
DIS   124.05 (-0.17%)
AMC   24.34 (+0.54%)
PYPL   100.94 (-0.56%)
PFE   49.68 (-0.14%)
NFLX   247.12 (-0.80%)
S&P 500   4,291.58 (-0.13%)
DOW   33,961.07 (+0.14%)
QQQ   331.49 (-0.47%)
AAPL   172.61 (-0.33%)
MSFT   292.63 (-0.29%)
META   178.63 (-1.25%)
GOOGL   121.82 (-0.21%)
AMZN   143.41 (+0.16%)
TSLA   939.16 (+1.21%)
NVDA   188.12 (-1.16%)
NIO   20.96 (-1.60%)
BABA   91.98 (-2.36%)
AMD   100.25 (-0.75%)
MU   63.67 (-1.59%)
T   18.40 (+0.05%)
CGC   3.67 (-3.93%)
F   16.35 (+0.18%)
GE   79.20 (-0.76%)
DIS   124.05 (-0.17%)
AMC   24.34 (+0.54%)
PYPL   100.94 (-0.56%)
PFE   49.68 (-0.14%)
NFLX   247.12 (-0.80%)
NASDAQ:RGLS

Regulus Therapeutics - RGLS Stock Forecast, Price & News

$1.80
-0.01 (-0.55%)
(As of 08/16/2022 09:30 AM ET)
Add
Compare
Today's Range
$1.80
$1.80
50-Day Range
$1.49
$21.00
52-Week Range
$1.42
$8.72
Volume
85 shs
Average Volume
139,595 shs
Market Capitalization
$26.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Regulus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,005.0% Upside
$20.00 Price Target
Short Interest
Healthy
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Regulus Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($2.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

290th out of 1,124 stocks

Pharmaceutical Preparations Industry

138th out of 555 stocks

RGLS stock logo

About Regulus Therapeutics (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Stock Performance

NASDAQ:RGLS opened at $1.81 on Tuesday. The stock has a market cap of $26.42 million, a P/E ratio of -0.67 and a beta of 1.99. The firm's fifty day simple moving average is $2.48 and its 200 day simple moving average is $2.50. Regulus Therapeutics has a twelve month low of $1.42 and a twelve month high of $8.72. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.07.

Analysts Set New Price Targets

Several brokerages have recently issued reports on RGLS. StockNews.com assumed coverage on shares of Regulus Therapeutics in a report on Tuesday, August 9th. They issued a "sell" rating on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Regulus Therapeutics in a report on Monday, May 9th.

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Stock News Headlines

Regulus Therapeutics Inc. (RGLS)
RGLS Regulus Therapeutics Inc.
Regulus Therapeutics GAAP EPS of -$0.07
Regulus Therapeutics Q4 2021 Earnings Preview
Regulus Therapeutics's Earnings: A Preview
See More Headlines
Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Company Calendar

Last Earnings
11/10/2021
Today
8/16/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGLS
CUSIP
75915K10
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+1,011.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-27,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.01 million
Book Value
$3.76 per share

Miscellaneous

Free Float
13,421,000
Market Cap
$26.33 million
Optionable
Optionable
Beta
1.99














RGLS Stock - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings
or view top-rated stocks.

What is Regulus Therapeutics' stock price forecast for 2022?

2 brokers have issued twelve-month price targets for Regulus Therapeutics' stock. Their RGLS share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 1,005.0% from the stock's current price.
View analysts price targets for RGLS
or view top-rated stocks among Wall Street analysts.

How have RGLS shares performed in 2022?

Regulus Therapeutics' stock was trading at $3.15 on January 1st, 2022. Since then, RGLS shares have decreased by 42.5% and is now trading at $1.81.
View the best growth stocks for 2022 here
.

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our RGLS earnings forecast
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.20. During the same period last year, the company earned ($0.40) earnings per share.

When did Regulus Therapeutics' stock split?

Regulus Therapeutics's stock reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.52%), Ikarian Capital LLC (0.72%), State Street Corp (0.29%), Renaissance Technologies LLC (0.19%), Commonwealth Equity Services LLC (0.15%) and Northern Trust Corp (0.12%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $1.81.

How much money does Regulus Therapeutics make?

Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $26.42 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-27,810,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com.

This page (NASDAQ:RGLS) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.